{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:54:56Z","timestamp":1792608896922,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T00:00:00Z","timestamp":1752969600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515010164"],"award-info":[{"award-number":["2023A1515010164"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Municipal Science and Technology Program key projects","doi-asserted-by":"publisher","award":["202206080011"],"award-info":[{"award-number":["202206080011"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272800"],"award-info":[{"award-number":["82272800"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103080"],"award-info":[{"award-number":["82103080"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.esmoop.2025.105561","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T01:09:57Z","timestamp":1755652197000},"page":"105561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["FGFR1-amplified colorectal cancer: a distinct prognostic subtype identified through integrated genomic and immunohistochemical profiling"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8866-1628","authenticated-orcid":false,"given":"X.","family":"Lyu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6873-8026","authenticated-orcid":false,"given":"Y.","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2025.105561_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"10449","key":"10.1016\/j.esmoop.2025.105561_bib2","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0140-6736(24)00360-X","article-title":"Colorectal cancer","volume":"404","author":"Eng","year":"2024","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105561_bib3","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105561_bib4","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105561_bib5","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105561_bib6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/jb\/mvq121","article-title":"Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease","volume":"149","author":"Itoh","year":"2011","journal-title":"J Biochem"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105561_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100641","article-title":"Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations","volume":"7","author":"Murugesan","year":"2022","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105561_bib8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"7923","key":"10.1016\/j.esmoop.2025.105561_bib9","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41586-022-05066-5","article-title":"Truncated FGFR2 is a clinically actionable oncogene in multiple cancers","volume":"608","author":"Zingg","year":"2022","journal-title":"Nature"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2025.105561_bib10","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1200\/JCO.2020.38.15_suppl.108","article-title":"FOENIX-CCA2: a phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements","volume":"38","author":"Goyal","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105561_bib11","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/S1470-2045(22)00603-9","article-title":"Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"23","author":"Wainberg","year":"2022","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105561_bib12","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105561_bib13","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105561_bib14","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study","volume":"24","author":"Pant","year":"2023","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105561_bib15","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","article-title":"FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions","volume":"21","author":"Katoh","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2025.105561_bib16","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1182\/blood-2022-163099","volume":"140","author":"Verstovsek","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.esmoop.2025.105561_bib17","first-page":"1654","article-title":"Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial","volume":"30","author":"Rod\u00f3n","year":"2024","journal-title":"Nat Med"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2025.105561_bib18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.2023.41.4_suppl.139","article-title":"A phase II single-arm study of the FGFR inhibitor pemigatinib in patients with metastatic colorectal cancer (mCRC) harboring FGF\/FGFR alterations","volume":"41","author":"Ciombor","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105561_bib19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-024-07747-9","article-title":"The genomic landscape of 2,023 colorectal cancers","volume":"633","author":"Cornish","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2025.105561_bib20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41586-024-07769-3","article-title":"Prognostic genome and transcriptome signatures in colorectal cancers","volume":"633","author":"Nunes","year":"2024","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105561_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100647","article-title":"Targeting the FGF\/FGFR axis and its co-alteration allies","volume":"7","author":"Uehara","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2025.105561_bib22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/PO.20.00178","article-title":"Noninvasive detection of polyclonal acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations","volume":"5","author":"Varghese","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"19","key":"10.1016\/j.esmoop.2025.105561_bib23","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1158\/1078-0432.CCR-23-3780","article-title":"Clinical value of liquid biopsy in patients with FGFR2 fusion\u2013positive cholangiocarcinoma during targeted therapy","volume":"30","author":"Gonz\u00e1lez-Medina","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.esmoop.2025.105561_bib24","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.1158\/1078-0432.CCR-21-1414","article-title":"Circulating tumor DNA analysis detects FGFR2 amplification and concurrent genomic alterations associated with FGFR inhibitor efficacy in advanced gastric cancer","volume":"27","author":"Jogo","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105561_bib25","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1093\/oncolo\/oyac180","article-title":"Comprehensive landscape of cyclin pathway gene alterations and co-occurrence with FGF\/FGFR aberrations across urinary tract tumors","volume":"28","author":"Jardim","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2025.105561_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107230","article-title":"Effect of FGFR alteration on prognosis in 1963 urothelial carcinoma patients with immune checkpoint inhibitors: implying combination of FGFR inhibitor and immunotherapy for FGFR-altered urothelial carcinoma","volume":"205","author":"Song","year":"2024","journal-title":"Pharmacol Res"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105561_bib27","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1158\/1078-0432.CCR-23-1317","article-title":"Landscape of clinical resistance mechanisms to FGFR inhibitors in FGFR2-altered cholangiocarcinoma","volume":"30","author":"Wu","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105561_bib28","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1089\/thy.2024.0216","article-title":"FGFR alterations in thyroid carcinoma: a novel class of primary drivers with significant therapeutic implications and secondary molecular events potentially mediating resistance in thyroid malignancy","volume":"34","author":"Sabbagh","year":"2024","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105561_bib29","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10120-014-0360-4","article-title":"Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma","volume":"18","author":"Nagatsuma","year":"2015","journal-title":"Gastric Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105561_bib30","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/JTO.0000000000000562","article-title":"Fibroblast growth factor receptor 1 and related ligands in small-cell lung cancer","volume":"10","author":"Zhang","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105561_bib31","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/1078-0432.CCR-19-1164","article-title":"Lucitanib for the treatment of HR(+)\/HER2(\u2212) metastatic breast cancer: results from the multicohort phase II FINESSE study","volume":"26","author":"Hui","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.esmoop.2025.105561_bib32","doi-asserted-by":"crossref","first-page":"6014","DOI":"10.1158\/1078-0432.CCR-08-0167","article-title":"Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer","volume":"14","author":"Behrens","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105561_bib33","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2967\/jnumed.123.266393","article-title":"Immunohistochemical FAP expression reflects (68)Ga-FAPI PET imaging properties of low- and high-grade intraductal papillary mucinous neoplasms and pancreatic ductal adenocarcinoma","volume":"65","author":"Spektor","year":"2024","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105561_bib34","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/cjp2.51","article-title":"FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non-small cell lung cancer","volume":"2","author":"Theelen","year":"2016","journal-title":"J Pathol Clin Res"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105561_bib35","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/jjco\/hyab104","article-title":"Cancer-related FGFR2 overexpression and gene amplification in Japanese patients with gastric cancer","volume":"51","author":"Minashi","year":"2021","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105561_bib36","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000398807","article-title":"Fibroblast growth factor receptor 1 gene copy number and mRNA expression in primary colorectal cancer and its clinicopathologic correlation","volume":"82","author":"Kwak","year":"2015","journal-title":"Pathobiology"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105561_bib37","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4143\/crt.2019.062","article-title":"Fibroblast growth factor receptor 1 (FGFR1) amplification detected by droplet digital polymerase chain reaction (ddPCR) is a prognostic factor in colorectal cancers","volume":"52","author":"Bae","year":"2020","journal-title":"Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105561_bib38","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s43018-023-00516-z","article-title":"Advances in antibody-based therapy in oncology","volume":"4","author":"Zinn","year":"2023","journal-title":"Nat Cancer"},{"issue":"10229","key":"10.1016\/j.esmoop.2025.105561_bib39","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0140-6736(20)30164-1","article-title":"Small molecules, big impact: 20 years of targeted therapy in oncology","volume":"395","author":"Bedard","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2025.105561_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41568-025-00824-9","article-title":"Acquired resistance in cancer: towards targeted therapeutic strategies","author":"Soragni","year":"2025","journal-title":"Nat Rev Cancer"},{"issue":"21","key":"10.1016\/j.esmoop.2025.105561_bib41","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1200\/JCO.19.01834","article-title":"Phase I escalation and expansion study of bemarituzumab (FPA144) in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma","volume":"38","author":"Catenacci","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105561_bib42","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1981202","article-title":"Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer","volume":"13","author":"Xiang","year":"2021","journal-title":"MAbs"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105561_bib43","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105561_bib44","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial","volume":"30","author":"Cort\u00e9s","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105561_bib45","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105561_bib46","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.annonc.2022.02.001","article-title":"FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF\/FGFR alterations and advanced malignancies","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2025.105561_bib47","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1158\/1078-0432.CCR-23-1283","article-title":"Clinical and genomic landscape of FGFR3-altered urothelial carcinoma and treatment outcomes with erdafitinib: a real-world experience","volume":"29","author":"Guercio","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105561_bib48","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov"},{"issue":"15","key":"10.1016\/j.esmoop.2025.105561_bib49","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1158\/1078-0432.CCR-15-1874","article-title":"FGFR1 is a potential prognostic biomarker and therapeutic target in head and neck squamous cell carcinoma","volume":"22","author":"Koole","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105561_bib50","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41392-022-01175-9","article-title":"RNA modifications: importance in immune cell biology and related diseases","volume":"7","author":"Cui","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105561_bib51","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41580-023-00676-x","article-title":"Lysosomes as coordinators of cellular catabolism, metabolic signalling and organ physiology","volume":"25","author":"Settembre","year":"2024","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105561_bib52","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.tcb.2025.01.002","article-title":"Endoplasmic reticulum (ER) protein degradation by ER-associated degradation and ER-phagy","volume":"35","author":"Wu","year":"2025","journal-title":"Trends Cell Biol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925014309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925014309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:46:05Z","timestamp":1762598765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925014309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2059702925014309"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105561","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FGFR1-amplified colorectal cancer: a distinct prognostic subtype identified through integrated genomic and immunohistochemical profiling","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105561","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105561"}}